



Silent cerebrovascular diseases and their significance

Byung-Woo Yoon MD, PhD.

Department of Neurology
Seoul National University Hospital








Figure . Age-adjusted and sex-adjusted stroke mortality rates are highest in eastern Europe, north Asia, central Africa, and the south Pacific.

Stroke Subtype



Increased proportion of disabled survivors (1995 – 2003)

(per 100,000 population)



Source : 1) incidence : KCDC(2004), 2) mortality : KNSO mortality data(1994~2005)


Brain Lesions


❖ Symptomatic

- **Ischemic stroke**
 - Lacunar infarction
 - Large artery atherosclerosis
- **Hemorrhagic stroke**

❖ Asymptomatic

- **Vascular lesion**
 - Asymptomatic vascular stenosis
- **Ischemic cerebral lesions**
 - White matter lesions (leukoaraiosis)
 - **Silent infarction**
- **Hemorrhagic cerebral lesions**
 - **Microbleeds**







Cerebral Microbleeds

Cerebral Microbleeds (CMB)

- ❖ Visualized by **GRE** sequence: Susceptibility effect
- ❖ **Small round dark lesion (<5 mm)**
- ❖ Throughout the whole brain areas



- ❖ **Mimicking lesions**
 - Calcification
 - Old hemorrhage
 - Vessel signal void



Meaning of CMB?

❖ CMB is related with ICH Offenbacher et al., *AJNR* 1996


- In 120 patients with ICH,
- 33% had "microbleeds" (33%)

❖ CMB is related with chronic HT Chan et al., *AJNR* 1996

Fazekas et al., *AJNR* 1999

❖ Pathology of CMB

- Hallmark of old hemorrhage



Hemosiderin laden macrophage

Ischemic Stroke Subtype



TABLE 2. Prevalence of Silent Microbleeds on T2*-Weighted MRI in Different Subtypes of Stroke

Stroke Subtype	Microbleeds			PVH Grade
	%	n	Range	
Cerebral infarction				
Atherothrombotic	20.8	0.63±1.53	0–6	1.3±0.90**
Cardioembolic	30.4*	2.5±5.6	0–21	1.3±0.82**
Lacunar	62.1**	7.4±16.1**	0–119	1.7±0.99**
Intracerebral hemorrhage	71.4**	9.1±13.8**	0–61	1.6±0.98**
Control	7.7	0.09±0.34	0–2	0.62±0.68


Values are mean±SD. PVHs are graded 0 (normal) through 3 (severe).

* $P < 0.05$, ** $P < 0.01$ vs control.

Kato et al., *Stroke* 2002




Prevalence of CMB



Group	n/N	Prevalence % (95%CI)
Healthy adults		
All studies	70/1411	5.0 (3.9–6.2)
Ischaemic stroke		
First-ever	53/231	22.9 (18.0–28.8)
Prior stroke	41/94	43.6 (34.0–53.7)
Not distinguished	266/750	35.5 (32.1–39.0)
All studies	360/1075	33.5 (30.7–36.4)
Non-traumatic intracerebral haemorrhage		
First-ever	246/475	51.8 (47.3–56.0)
Prior stroke	47/57	82.5 (70.6–90.2)
Not distinguished	247/362	68.2 (63.3–72.8)
All studies	540/894	60.4 (57.2–63.6)
Ischaemic and haemorrhagic stroke (mixed)		
First-ever	65/117	55.6 (46.5–64.2)
Prior stroke	33/47	70.2 (56.0–81.3)
Not distinguished	229/556	41.2 (37.2–45.3)
All studies	327/720	45.4 (41.8–49.1)

SNUH health care clinic data: 5%



Risk Factors for Microbleeds





Table 3 Influence of comorbid conditions on the prevalence of BMBs

Risk factor	Healthy adults			Adults with cerebrovascular diseases		
	Studies	Sample size	Odds ratio, 95% CI	Studies	Sample size	Odds ratio, 95% CI
Male gender	4	1411	1.4, 0.9–2.3	16	1275	1.2, 0.98–1.5
Hypertension	4	1411	3.9, 2.4–6.4	12	1037	2.3, 1.7–3.0
Smoking	4	1411	1.0, 0.5–2.0	11	1107	0.7, 0.5–0.9
Ischaemic heart disease	2	730	1.9, 0.8–4.4	7	628	0.6, 0.4–1.02
Diabetes mellitus	4	1411	2.2, 1.2–4.2	14	1303	0.9, 0.7–1.1

❖ Close relationship

- Tanaka et al (1999): ICH
- Roob et al (1999): Healthy
- Tsushima et al (2003): Healthy
- Lee et al (2002): NR Adm
- Chan et al. (1996): NR Adm




❖ No relationship

- Jeerakathil et al (2003): Framingham
- Roob et al (2000): ICH
- Jeong et al (2004): ICH
- Greenberg et al (2004): Lobar ICH
- Fan et al. (2003): Acute ischemic stroke

Quantitative measurement of HT

❖ HT severity and LVMI

- HT severity is reflected by **left ventricular (LV) hypertrophy**
- **LV mass index (LVMI)**
 - **Calculation using parameters in TTE**
 - Devereux and Reichek (1977)



$$\text{LVMI (g/m}^2\text{)} = [1.05 \times \{(\text{LVEDD} + \text{IVSTd} + \text{PWTd})^3 - (\text{LVEDD})^3\} - 13.6] / \text{BSA}$$

-BSA confounder adjustment

-Accurate LVH index

CMB and LVMI

Left ventricular hypertrophy is associated with cerebral microbleeds in hypertensive patients

S.-H. Lee, MD; J.-M. Park, MD; S.-J. Kwon, MD; H. Kim, PhD; Y.-H. Kim, MPH; J.-K. Roh, MD, PhD; and B.-W. Yoon, MD, PhD

Neurology 2004;63:16-21

Table 5 Ordinal logistic regression analysis

Parameter	Odds ratio	95% CI	<i>p</i>
CMB in whole-brain area			
Grade of LV mass index	1.53	1.09–2.14	0.01
Previous stroke	2.47	1.17–5.22	0.02
Leukoaraiosis			
Grade of LV mass index	1.51	1.07–2.12	0.02
Old age, >75 y	1.06	1.02–1.1	0.01
Diabetes	3.67	1.07–2.12	0.01
CMB in subcortical white matter			
Previous stroke	2.31	1.05–5.06	0.04
CMB in central gray matter			
Body mass index	0.87	0.76–0.99	0.03
Grade of LV mass index	2.14	1.48–3.10	<0.01
Previous stroke	2.19	1.01–4.73	0.04
CMB in infratentorial area			
Grade of LV mass index	2.13	1.40–3.22	<0.01



The Other Risk Factors

❖ Old age

- Roob et al., *Neurology* 1999; Jeerakathil et al., *Stroke* 2004

❖ Cerebral amyloid angiopathy (CAA)

- Greenberg et al., *Neurology* 1996

❖ Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)

- A hereditary form of small-vessel disease
- Lesnik Oberstein et al., *Neurology* 2001; Dichgans et al., *Stroke* 2002

❖ Low serum cholesterol

- Lee et al., *Stroke* 2002
 - The lowest quartile of **total cholesterol** (< 165 mg/dL; OR = 10.9)
-



CMB and low cholesterol

Low Concentration of Serum Total Cholesterol Is Associated With Multifocal Signal Loss Lesions on Gradient-Echo Magnetic Resonance Imaging

Analysis of Risk Factors for Multifocal Signal Loss Lesions

Seung-Hoon Lee, MD; Hee-Joon Bae, MD; Byung-Woo Yoon, MD, PhD; Ho Kim, PhD; Dong-Eog Kim, MD; Jae-Kyu Roh, MD, PhD. *Stroke*. 2002;33:2845-2849.

TABLE 3. Comparison of Lipid Profiles Among the Groups of MSLLs



	Grade of MSLL				<i>P</i> *
	Absent	Mild	Moderate	Severe	
TC, mmol/L	4.97±0.98	4.78±1.09	5.01±1.01	4.16±0.72	0.019
LDLC, mmol/L	3.02±0.86	2.85±0.95	3.18±0.39	2.30±0.62	0.009
HDLC, mmol/L	1.24±0.36	1.38±0.49	1.33±0.41	1.11±0.34	0.241†
TG, mmol/L	1.57±0.87	1.19±0.73	1.06±0.55	1.69±1.17	0.083†


TABLE 5. Multivariate Analysis

	OR	95% CI
Hypertension	3.42	1.17–9.97
Leukoaraiosis	4.62	2.87–7.41
TC <25th percentile	10.91	3.98–25.57
TC >75th percentile	2.45	0.96–6.26
HDLC <25th percentile	0.92	0.37–2.33
HDLC >75th percentile	3.46	1.45–8.29

Cumulative logits model.

Clinical Implications





Clinical Implications

1. Prediction of ICH
 2. Prediction of hemorrhagic transformation
 3. Caution with antiplatelet or anticoagulant treatment
-



Prediction of ICH

❖ Patients with HT

- Who will have **ischemic** vs **hemorrhagic** stroke?
 - **Microbleeds** might be a prediction tool for future event?
-



Regional Association

Cerebral microbleeds are regionally associated with intracerebral hemorrhage

S.H. Lee, MD; H.J. Bae, MD; S.J. Kwon, MD; H. Kim, PhD; Y.H. Kim, MPH; B.W. Yoon, MD, PhD
Neurology 2004;62:72-76

- ❖ Cross-sectional design
- ❖ 227 stroke patients (144 ischemic; 83 hemorrhagic)
- ❖ *In situ* correlation of distribution

Table 3 Logistic regression analysis for ICH in CSC and DGM

Variable	CSC			DGM		
	<i>p</i>	OR	(95% CI)	<i>p</i>	OR	(95% CI)
Leukoaraiosis	0.46	0.78	(0.41–1.50)	0.78	1.07	(0.66–1.75)
CMB location						
CSC CMB	<0.01	5.50	(2.68–11.27)	0.27	1.33	(0.80–2.21)
DGM CMB	0.09	0.51	(0.24–1.11)	<0.01	2.55	(1.46–4.45)
IT CMB	0.73	1.13	(0.56–2.31)	0.10	0.60	(0.32–1.10)
Old lacune location						
CSC lacune	0.49	0.74	(0.32–1.73)	0.95	1.02	(0.58–1.80)
DGM lacune	0.32	1.35	(0.74–2.48)	0.88	0.97	(0.63–1.48)
IT lacune	0.29	0.60	(0.24–1.54)	<0.01	0.36	(0.17–0.77)

ICH = intracerebral hemorrhage; CSC = corticosubcortical area; DGM = deep gray matter; OR = odds ratio; IT = infratentorial area.

Evidences in Prospective Data

Cerebral Microbleeds as a Risk Factor for Subsequent Intracerebral Hemorrhages Among Patients With Acute Ischemic Stroke

Fan et al. Stroke 2003





TABLE 2. Vascular Events During Follow-Up of 121 Patients


	Total (n=121), n (%)	MBs(+) (n=43), n (%)	MBs(-) (n=78), n (%)	P
Recurrent stroke	16 (13.2)	9 (20.9)	7 (9.0)	0.157
Intracerebral hemorrhage	5 (4.13)	4 (9.3)	1 (1.28)	0.053*
Cerebral infarction	11 (9.01)	5 (11.6)	6 (7.7)	0.747*
Ischemic heart disease	5 (4.13)	1 (2.33)	4 (5.13)	0.654*
Death	14 (11.6)	5 (11.6)	9 (11.5)	1.0*

*Fisher's exact test.

Hemorrhage Burden Predicts Recurrent Intracerebral Hemorrhage After Lobar Hemorrhage

Greenberg et al. Stroke 2004





1. Prediction of ICH
2. **Prediction of hemorrhagic transformation**
3. Caution with antiplatelet or anticoagulant treatment

The First Suggestions

❖ After thrombolysis

- Kidwell et al., *Stroke* 2002
- Pretreatment GRE MRI before IA thrombolysis (n=41)
- 5 patients with microbleeds
- Major symptomatic hemorrhage (n=5)
- **Patients with microbleeds: n=1 ($p = 0.049$)**

❖ After acute stroke in general

- Nighoghossian et al., *Stroke* 2002
- 100 patients with acute ischemic stroke: 20 patients with microbleeds
- Early hemorrhagic transformation was occurred 26 patients in F/U GRE or CT: 10 patients with microbleeds
- **Microbleeds are an independent risk factor for early hemorrhagic transformation ($p < 0.0001$)**





Contradictory Data

Thrombolysis for Ischemic Stroke in Patients with Old Microbleeds on Pretreatment MRI

Laurent Derex^{a, d} Norbert Nighoghossian^{a, d} Marc Hermier^{c, d}
Patrice Adeleine^b Frédéric Philippeau^a Jérôme Honnorat^a Hasan Yilmaz^c
Pascal Dardel^c Jean-Claude Froment^{c, d} Paul Trouillas^a

Cerebrovasc Dis 2004;17:238–241

CME Clinical importance of microbleeds in patients receiving IV thrombolysis

W. Kakuda, MD; V.N. Thijs, MD, PhD; M.G. Lansberg, MD, PhD; R. Bammer, PhD; L. Wechsler, MD; S. Kemp, BS; M.E. Moseley, PhD; M.P. Marks, MD; and G.W. Albers, MD, for the DEFUSE Investigators*

NEUROLOGY 2005;65:1175–1178



After Thrombolysis

Bleeding Risk Analysis in Stroke Imaging Before ThromboLysis (BRASIL)

Pooled Analysis of T2*-Weighted Magnetic Resonance Imaging Data From 570 Patients

Fiehler et al., *Stroke* 2007

- ❖ A pooled analysis of 570 patients in 13 centers in Europe, North America, and Asia
- ❖ Microbleeds within 6 hours from onset
- ❖ No controlled, no randomized study, retrospective sampling in some centers
- ❖ Proportions of patients with symptomatic hemorrhage
 - 5.8% (95% CI, 1.9 to 13.0) in the presence of microbleeds
 - 2.7% (95% CI, 1.4 to 4.5) in patients without CMB
 - No significant absolute increase ($P=0.170$, Fisher's exact test)
- ❖ **If there is any increased risk of ICH attributable to microbleeds, it is likely to be small and unlikely to exceed the benefits of thrombolytic therapy.**



Without Thrombolysis

Does microbleed predict haemorrhagic transformation after acute atherothrombotic or cardioembolic stroke?

S-H Lee,^{1,2} B-S Kang,¹ N Kim,¹ J J *J Neurol Neurosurg Psychiatry* 2008;**79**:913–916.

❖ SNUH study

- Study population : 380 among 1,034 acute ischemic stroke
 - Large artery atherosclerosis (n=219)
 - Cardioembolism (n=161)
- lack of significance between MBs and HTf
 - Presence vs absence of CMB
 - Number of CMB
 - Stroke mechanism
- **Conclusion**
 - **Underlying MBs do not predict incident HTf after acute ischemic stroke.**


Difference in ICH Mechanism


❖ ICH

- ICH was associated with **chronic hypertensive microangiopathy** such as lipohyalinosis, microatheroma, and microaneurysm
- Microbleeds:


❖ Hemorrhagic transformation

- Associated with **ischemic injury to the microvasculature** such as loss of basal laminar in extensive brain infarction





1. Prediction of ICH
 2. Prediction of hemorrhagic transformation
 3. **Caution with antiplatelet agents or anticoagulant**
-



AFTER ASPIRIN MEDICATION

Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages

Wong et al, *Neurology* 2003;60:511-513

Characteristics	Symptomatic intracerebral hemorrhage		
	Yes (n = 21)	No (n = 21)	p Value
Aspirin users	21	21	
	Asymptomatic microhemorrhages on GRE MRI		
Presence	19	7	<0.001
Mean no. (range)	13.3 (0-54)	0.4 (0-2)	<0.001
Distribution			
Lobar region	16	5	0.002
Basal ganglia	13	3	0.002
Thalamus	13	0	<0.001
Pons	10	0	<0.001
Cerebellum	10	0	<0.001



Association

AFTER WARFARIN MEDICATION

Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage

Lee SH et al. Neurology[®] 2009;72:171-176

SNUH study population

Case 24 vs. control 48


Variables	OR	95% CI	p Value
PT-INR	4.13	1.40-12.77	0.011
Presence of microbleeds	83.12	5.96-1,159.10	0.001
WMH	3.60	0.70-113.64	0.093



Another question

Is antiplatelet or anticoagulant treatment associated with a higher prevalence of CMBs?





- ❖ Some studies provide data about the use of antiplatelet/anticoagulant agents at the time of brain MRI examination.
- ❖ No association with **antiplatelet agents** and increased risk of possessing CMBs
 - Ischemic stroke (Nighoghossian et al., 2002; Schonewille et al., 2005), ICH (Jeong et al., 2004; Lee et al., 2006), CADASIL (Lesnik Oberstein et al., 2001)
- ❖ No association with **anticoagulant** treatment and increased risk of possessing CMBs
 - Ischemic stroke (Schonewille et al., 2005), ICH (Jeong et al., 2004)



Silent infarction

Silent infarct

- ❖ Infarct occurred at non-eloquent area
- ❖ Perilesional gliosis (+)
- ❖ Differential point: Dilated perivascular space



Prevalence

Incidental Findings on Brain MRI in the General Population

N Engl J Med 2007;357:1821-8.

- ❖ As a related study of Rotterdam Scan Study
- ❖ Age > 45Y

Table 1. Incidental Findings on 2000 MRI Scans.*

Finding	No. (%)
Asymptomatic brain infarct†	145 (7.2)
Lacunar infarct	112 (5.6)
Cortical infarct	41 (2.0)
Primary tumors, benign	31 (1.6)
Meningioma	18 (0.9)
Vestibular schwannoma	4 (0.2)
Intracranial lipoma‡	2 (0.1)
Trigeminal schwannoma	1 (<0.1)
Pituitary adenoma	6 (0.3)


Silent brain infarcts: a systematic review

	Mean age (range), years	SBI, %
Helsinki Aging Brain Study (HABS), 1995 ⁹	72 (56-88)	16
Cardiovascular Health Study (CHS), 1997 ¹⁰	75 (65-97)	28
Atherosclerosis Risk in Communities (ARIC) Study, 1998 ¹¹	63 (55-72)	11
Rotterdam Scan Study (RSS), 2002 ¹²	72 (60-90)	20
National Institute for Longevity Sciences - Longitudinal Study of Aging (NILS-LSA), 2003 ¹³	59 (40-79)	10
Memory and Morbidity in Augsburg Elderly (MEMO) study, 2004 ¹⁴	72 (65-83)	13
Framingham Heart Study (FHS), 2005 ¹⁵	62 (34-97)	12
Austrian Stroke Prevention Study (ASPS), 2006 ¹⁶	64 (50-75)	8


Lancet Neurol 2007; 6: 611-19

Location

Silent infarcts




Vermeer, NEJM 2003




Risk factors

Age

- ❖ Rotterdam study
- ❖ Age 60-90
- ❖ MRI: mean 3.4 yr later (n=668)
- ❖ At least 1 new infarct in 14% (87% of these silent)



Vermeer et al. Stroke 2003




Lancet Neurol 2007; 6: 611-19

Coexistence of risk factors

- ❖ In asymptomatic HT pts. (n=360)
- ❖ Infarcts more common if DM also present


	DM + HT	Just HT
≥ 1 infarct	82%	58%
≥ 3 infarct	62%	35%

Eguchi et al. Stroke 2003




Blood pressure fluctuation


- A) Dipper : nocturnal BP decrease (10-19%) compared to daytime BP
- B) Non-Dipper: nocturnal BP decrease less than 10% compared to daytime BP
- C) Extreme dipper: nocturnal BP decrease more than 20%
- D) Reverse dipper : nocturnal BP increase




A



B





C



D

Blood pressure fluctuation



Kario et al. Hypertension 2001

Metabolic syndrome

Metabolic Syndrome as an Independent Risk Factor of Silent Brain Infarction in Healthy People


Hyung-Min Kwon, MD; Beom Joon Kim, MD; Seung-Hoon Lee, MD; Seung Ho Choi, MD;
Byung-Hee Oh, MD, PhD; Byung-Woo Yoon, MD, PhD

❖ $88/1588 = 5.5\%$, (5.9%, >40Y)

TABLE 1. Demographic Data of Study Subjects and Prevalence of SBI

Age, y	Prevalence		
	Male	Female	Total
<40	1/86 (1.2)	1/57 (1.8)	2/143 (1.4)
40–49	8/247 (3.2)	4/159 (2.5)	12/406 (3.0)
50–59	12/315 (3.8)	8/240 (3.3)	20/555 (3.6)
60–69	21/217 (9.7)	15/164 (9.1)	36/381 (9.4)
≥70	11/62 (17.7)	7/41 (17.1)	18/103 (17.5)

Values in parentheses represent percentages.



MetS factor

A marker for further stroke

Silent Brain Infarcts and White Matter Lesions Increase Stroke Risk in the General Population


The Rotterdam Scan Study

Sarah E. Vermeer, MD; Monika Hollander, MD; Ewoud J. van Dijk, MD;
Albert Hofman, MD; Peter J. Koudstaal, MD; Monique M.B. Breteler, MD

(*Stroke*. 2003;34:1126-1129.)

TABLE 2. Relationship Between the Presence of Silent Brain Infarcts, Tertiles of Periventricular, and Subcortical White Matter Lesions (WML) on MRI and the Risk of Stroke

	Risk of Stroke (Hazard Ratio [95% CI])		
	Adjusted for Age and Sex	Adjusted for Stroke Risk Factors*	Adjusted for MRI Lesions†
Silent brain infarcts			
Absent	1 (reference)	1 (reference)	1 (reference)
Present	3.6 (2.1–6.1)	3.9 (2.3–6.8)	3.3 (1.8–5.9)



Silent infarction and cognitive decline

- ❖ Infarction occurred at the area of non-motor and non-sensory area
- ❖ Mainly frontal subcortex and basal ganglia
- ❖ Frontal executive function

Table 2. Relation between the Presence of Silent Brain Infarcts at Base Line, the Severity of Periventricular and Subcortical White-Matter Lesions, and the Risk of Dementia.

Variable	Hazard Ratio (95% Confidence Interval)	
	Adjusted for Age, Sex, and Level of Education	Adjusted for Age, Sex, Level of Education, and MRI Measures*
Silent brain infarcts (yes vs. no)	2.26 (1.09–4.70)	2.03 (0.91–4.55)
Severity of periventricular white-matter lesions (per SD increase)	1.59 (1.13–2.25)	1.47 (0.92–2.35)
Severity of subcortical white-matter lesions (per SD increase)	1.21 (0.96–1.53)	0.92 (0.65–1.29)

Vermeer et al, NEJM 2003



Summary (1)

- ❖ **Microbleeds are associated with...**
 1. ICH in the patients with ischemic stroke
 2. Recurrent ICH
 3. ICH occurred in the patients with aspirin/warfarin(?)

 - ❖ **Microbleeds are NOT associated with...**
 1. Hemorrhagic transformation after thrombolysis
 2. Early hemorrhagic transformation in the acute phase of ischemic stroke

 - ❖ Microbleeds may **reflect baseline status of BBB disruption.**
-



Summary (2)

❖ Silent infarction

- Associated with stroke risk factors
 - associated with metabolic syndrome
 - Predicts future stroke risk (HR 3.3)
 - Is associated with cognitive decline
 - **Future studies will have to show whether screening and treating high-risk patients can effectively reduce the risk of further infarcts, stroke, and dementia.**
-

Thank You !

